Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 1;216(suppl_9):S843-S846.
doi: 10.1093/infdis/jix398.

Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update

Robert W Shafer  1
Affiliations

Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update

Robert W Shafer. J Infect Dis. .

Abstract

As treatment options coalesce around a smaller number of antiretroviral drugs (ARVs), data are emerging on the drug resistance mutations (DRMs) selected by the most widely used ARVs and on the impact of these DRMs on ARV susceptibility and virological response to first- and later-line treatment regimens. Recent studies have described the DRMs that emerge in patients receiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir, and the integrase inhibitors raltegravir and elvitegravir. Several small studies have described DRMs that emerge in patients receiving dolutegravir.

Keywords: antiviral drug therapy; human immunodeficiency virus type 1; integrase; protease; reverse transcriptase.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wensing AM, Calvez V, Gunthard HF et al. . 2017 update of the drug resistance mutations in HIV-1. Top Antivir Med 2017; 24:132–3. - PMC - PubMed
    1. Paredes R, Tzou PL, van Zyl G et al. . Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One 2017; 12:e0181357. - PMC - PubMed
    1. Menéndez-Arias L. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments. Antiviral Res 2013; 98:93–120. - PubMed
    1. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol 2016; 46:292–307. - PMC - PubMed
    1. Rhee SY, Varghese V, Holmes SP et al. . Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration. EBioMedicine 2017; 18:225–35. - PMC - PubMed